20 Nov 2026

Covid-19 Inquiry finds testing plans inadequate

The IBMS agrees that the UK was underprepared and says future pandemic testing should build on the capacity of NHS and public health laboratories, with HCPC-registered biomedical scientists leading the response.

 

The UK Covid-19 Inquiry’s report on test, trace and isolate, published on 19 November, finds that the UK entered the pandemic without an adequate plan to expand testing. Scientists had developed an effective test by mid-January 2020. By March, shortages of tests and equipment and limited capacity to process samples contributed to the decision to pause widespread community testing and contact tracing.

The report says the early response was hampered by “a lack of knowledge of the existing testing capabilities of the private and public sectors” and by a failure to work with them. It recommends that the four governments keep an up-to-date record of what academic, clinical and research laboratories can test, share that information and plan how to increase their testing capacity quickly in an emergency. The Institute of Biomedical Science supports that recommendation and Baroness Hallett’s conclusion that future plans should build on existing infrastructure.

David Wells, IBMS Chief Executive, said:

Biomedical scientists running diagnostic services can tell you how many more samples their laboratory could test tomorrow, what would hold them back and which services their patients still need that day. That is the starting point for a credible testing plan. We are ready to work with the NHS and public health agencies to put that knowledge to use before the next emergency.

In spring 2020, biomedical scientists helped introduce testing for a new virus while keeping diagnostic services running for other patients. In evidence to the Inquiry, the IBMS reported that NHS laboratories doubled their Covid-19 testing capacity in one week in April. The IBMS believes those teams should have been involved earlier in planning the testing programme. Future plans should establish how much more testing NHS and public health laboratories can deliver and what staff, equipment and supplies they would need.

Where academic or independent laboratories are needed to add capacity, NHS and public health laboratories should coordinate their work. Any laboratory providing results for patients should meet the same accreditation and quality standards as NHS diagnostic laboratories, with HCPC-registered biomedical scientists responsible for the quality of results.

In England, NHS and independent providers carrying out regulated diagnostic procedures must register with the Care Quality Commission (CQC). In December 2020, legislation exempted SARS-CoV-2 testing from that requirement, including the processing, analysis and reporting of results. Separate regulations introduced a staged accreditation scheme for commercial testing, allowing providers to operate while working towards accreditation by the United Kingdom Accreditation Service (UKAS). The IBMS believes CQC registration should continue to apply when diagnostic testing expands in a future emergency, to protect patients.

In 2021, Immensa’s private laboratory in Wolverhampton was commissioned to provide extra capacity for NHS Test and Trace. The Government told Parliament that these contracts allowed laboratories to operate while working towards accreditation. UKAS confirmed that Immensa held no UKAS accreditation at the time. Staff set the thresholds for reporting positive and negative PCR results incorrectly. The UK Health Security Agency (UKHSA) investigation estimated that this could have led the laboratory to report around 39,000 results as negative when they should have been positive.

In England, the UK Government’s pandemic preparedness strategy commits to closer working between UKHSA and NHS laboratories. It provides for UKHSA to use commercial contracts if national testing demand exceeds NHS capacity during a major incident. The IBMS welcomed the strategy in March. UKHSA tested its plan to expand diagnostic testing during Exercise Pegasus, the national pandemic exercise held in autumn 2025.

The IBMS is asking governments and public health agencies in all four nations to build on that work with biomedical scientists. Together they should agree when to bring in additional laboratories, how results will reach patients, clinicians and public health teams, and how routine diagnostic services will continue. Governments should fund the staff, training and infrastructure those plans require and test the arrangements in future exercises.

Dr Sarah Pitt, IBMS President, said:

We can’t assume the next pandemic will follow the pattern of influenza or Covid-19. How an infection spreads and who is most at risk will shape how to organise testing. Biomedical scientists working in diagnostic microbiology should be part of those decisions from the outset.

 

Finished reading?

Log CPD activity